

- E. Sharpless, C. M. Perou, W. Y. Kim, S. M. Gomez, X. Chen, J. Jin, S. V. Frye, H. S. Earp, L. M. Graves and G. L. Johnson (2012). "Dynamic reprogramming of the kinase in response to targeted MEK inhibition in triple-negative breast cancer." *Cell* 149(2): 307-321.
- [0281] Faber, A. C., E. M. Coffee, C. Costa, A. Dastur, H. Ebi, A. N. Hata, A. T. Yeo, E. J. Edelman, Y. Song, A. T. Tam, J. L. Boisvert, R. J. Milano, J. Roper, D. P. Kodack, R. K. Jain, R. B. Corcoran, M. N. Rivera, S. Ramaswamy, K. E. Hung, C. H. Benes and J. A. Engelman (2014). "mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1." *Cancer Discov* 4(1): 42-52.
- [0282] Fearon, E. R. (2011). "Molecular genetics of colorectal cancer." *Annu Rev Pathol* 6: 479-507.
- [0283] Horn, T., T. Sandmann, B. Fischer, E. Axelsson, W. Huber and M. Boutros (2011). "Mapping of signaling networks through synthetic genetic interaction analysis by RNAi." *Nat Methods* 8(4): 341-346.
- [0284] Ji, Z., C. N. Njauw, M. Taylor, V. Neel, K. T. Flaherty and H. Tsao (2012). "p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition." *J Invest Dermatol* 132(2): 356-364.
- [0285] Katayama, R., A. T. Shaw, T. M. Khan, M. Minokudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C. Wain, A. T. Yeo, C. Benes, L. Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Lafrate and J. A. Engelman (2012). "Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers." *Sci Transl Med* 4(120): 120ra117.
- [0286] Lehar, J., A. Krueger, G. Zimmermann and A. Borisy (2008). "High-order combination effects and biological robustness." *Mol Syst Biol* 4: 215.
- [0287] Lito, P., N. Rosen and D. B. Solit (2013). "Tumor adaptation and resistance to RAF inhibitors." *Nat Med* 19(11): 1401-1409.
- [0288] Pau, G., F. Fuchs, O. Sklyar, M. Boutros and W. Huber (2010). "EBImage—an R package for image processing with applications to cellular phenotypes." *Bioinformatics* 26(7): 979-981.
- [0289] Porter, K., A. Babiker, K. Bhaskaran, J. Darbyshire, P. Pezzotti, K. Porter, A. S. Walker and C. Collaboration (2003). "Determinants of survival following HIV-1 seroconversion after the introduction of HAART." *Lancet* 362(9392): 1267-1274.
- [0290] Robert, C., B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakowski, M. Lichinitser, R. Dummer, F. Grange, L. Mortier, V. Chiarion-Silini, K. Drucis, I. Krajsova, A. Hauschild, P. Lorigan, P. Wolter, G. V. Long, K. Flaherty, P. Nathan, A. Ribas, A. M. Martin, P. Sun, W. Crist, J. Legos, S. D. Rubin, S. M. Little and D. Schadendorf (2015). "Improved overall survival in melanoma with combined dabrafenib and trametinib." *N Engl J Med* 372(1): 30-39.
- [0291] Safaei Ardekani, G., S. M. Jafarnejad, L. Tan, A. Saeedi and G. Li (2012). "The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis." *PLoS One* 7(10): e47054.
- [0292] Shoemaker, R. H. (2006). "The NCI60 human tumour cell line anticancer drug screen." *Nat Rev Cancer* 6(10): 813-823.
- [0293] Solit, D. B. and N. Rosen (2014). "Towards a unified model of RAF inhibitor resistance." *Cancer Discov* 4(1): 27-30.
- [0294] Sullivan, R. J. and K. T. Flaherty (2013). "Resistance to BRAF-targeted therapy in melanoma." *Eur J Cancer* 49(6): 1297-1304.
- [0295] Turner, N. C., J. Ro, F. Andre, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, C. Huang Bartlett, K. Zhang, C. Giorgetti, S. Randolph, M. Koehler and M. Cristofanilli (2015). "Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer." *N Engl J Med*
1. A pharmaceutical combination comprising
 - (a) an MDM2 inhibitor selected from (6S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-insepropan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one, or a pharmaceutically acceptable salt thereof, and (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, or a pharmaceutically acceptable salt thereof; and
 - (b)
 - (i) a MEK inhibitor selected from the group consisting of trametinib, 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide, (S)-5-fluoro-2-(2-fluoro-4-(methylthio)phenylamino)-N-(2-hydroxypropoxy)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide, PD0325901, PD-184352, RDEA119, XL518, AS-701255, AS-701173, AS703026, RDEA436, E6201, RO4987655, RG7167, and RG7420 or a pharmaceutically acceptable salt thereof, and/or
 - (ii) Bcl2 inhibitor selected from the group consisting of ABT-737, ABT-263 (navitoclax) and ABT-199, or a pharmaceutically acceptable salt thereof.
 2. The pharmaceutical combination according to claim 1 comprising
 - (a) an MDM2 inhibitor selected from (6S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one, or a pharmaceutically acceptable salt thereof, and (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, or a pharmaceutically acceptable salt thereof; and
 - (b) the MEK inhibitor.
 3. The pharmaceutical combination according to claim 1, wherein the MEK inhibitor is trametinib, or a pharmaceutically acceptable salt thereof.
 4. The pharmaceutical combination comprising
 - (a) an MDM2 inhibitor selected from (6S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one, or a pharmaceutically acceptable salt thereof, and (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, or a pharmaceutically acceptable salt thereof; and
 - (b) the Bcl2 inhibitor.